$1108.07
Revenue is up for the last 2 quarters, 928.73M → 982.11M (in $), with an average increase of 5.4% per quarter
Netprofit is up for the last 2 quarters, 188.42M → 213.92M (in $), with an average increase of 11.9% per quarter
In the last 1 year, Idexx Laboratories, Inc. has given 34.2% return, outperforming this stock by 32.0%
0.17%
Downside
Day's Volatility :2.29%
Upside
2.13%
3.84%
Downside
52 Weeks Volatility :34.06%
Upside
31.43%
Period | Mettler-toledo International Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -15.52% | -3.0% | -3.6% |
6 Months | -26.12% | 0.5% | 5.9% |
1 Year | 2.21% | 6.3% | 19.6% |
3 Years | 14.74% | 22.1% | 27.5% |
Market Capitalization | 24.5B |
Book Value | - $4.1 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 39.52 |
PE Ratio | 28.3 |
PEG Ratio | 2.81 |
Wall Street Target Price | 1357.2 |
Profit Margin | 22.48% |
Operating Margin TTM | 29.91% |
Return On Assets TTM | 22.05% |
Return On Equity TTM | 29.51% |
Revenue TTM | 4.0B |
Revenue Per Share TTM | 178.46 |
Quarterly Revenue Growth YOY | 0.4% |
Gross Profit TTM | 2.3B |
EBITDA | 1.3B |
Diluted Eps TTM | 39.52 |
Quarterly Earnings Growth YOY | 0.04 |
EPS Estimate Current Year | 40.69 |
EPS Estimate Next Year | 45.06 |
EPS Estimate Current Quarter | 9.97 |
EPS Estimate Next Quarter | 11.42 |
What analysts predicted
Upside of 22.48%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↑ 8.64% |
Net Income | 376.0M | ↓ 2.18% |
Net Profit Margin | 13.8% | ↓ 1.52% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.9B | ↑ 7.73% |
Net Income | 512.6M | ↑ 36.34% |
Net Profit Margin | 17.46% | ↑ 3.66% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 2.49% |
Net Income | 561.1M | ↑ 9.46% |
Net Profit Margin | 18.65% | ↑ 1.19% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 3.1B | ↑ 2.54% |
Net Income | 602.7M | ↑ 7.42% |
Net Profit Margin | 19.54% | ↑ 0.89% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 20.51% |
Net Income | 769.0M | ↑ 27.58% |
Net Profit Margin | 20.68% | ↑ 1.14% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.9B | ↑ 5.43% |
Net Income | 872.5M | ↑ 13.46% |
Net Profit Margin | 22.26% | ↑ 1.58% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 897.8M | ↓ 13.44% |
Net Income | 174.0M | ↓ 24.63% |
Net Profit Margin | 19.38% | ↓ 2.88% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 978.4M | ↑ 8.98% |
Net Income | 212.1M | ↑ 21.88% |
Net Profit Margin | 21.68% | ↑ 2.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 985.8M | ↑ 0.76% |
Net Income | 220.6M | ↑ 4.02% |
Net Profit Margin | 22.38% | ↑ 0.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↑ 7.29% |
Net Income | 265.8M | ↑ 20.51% |
Net Profit Margin | 25.13% | ↑ 2.75% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 928.7M | ↓ 12.19% |
Net Income | 188.4M | ↓ 29.12% |
Net Profit Margin | 20.29% | ↓ 4.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 982.1M | ↑ 5.75% |
Net Income | 213.9M | ↑ 13.53% |
Net Profit Margin | 21.78% | ↑ 1.49% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 17.68% |
Total Liabilities | 2.0B | ↑ 15.63% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 2.71% |
Total Liabilities | 2.0B | ↑ 1.31% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 6.51% |
Total Liabilities | 2.4B | ↑ 16.75% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 0.9% |
Total Liabilities | 2.5B | ↑ 6.9% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 18.2% |
Total Liabilities | 3.2B | ↑ 24.63% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↑ 4.98% |
Total Liabilities | 3.5B | ↑ 9.9% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↑ 0.88% |
Total Liabilities | 3.3B | ↑ 3.68% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↓ 0.59% |
Total Liabilities | 3.3B | ↑ 1.76% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↓ 1.26% |
Total Liabilities | 3.4B | ↑ 1.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.5B | ↑ 6.01% |
Total Liabilities | 3.5B | ↑ 2.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↓ 2.36% |
Total Liabilities | 3.4B | ↓ 0.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.4B | ↓ 1.16% |
Total Liabilities | 3.5B | ↑ 0.75% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 516.3M | ↑ 16.53% |
Investing Cash Flow | -217.3M | ↓ 6.1% |
Financing Cash Flow | -319.5M | ↑ 118.97% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 565.0M | ↑ 9.43% |
Investing Cash Flow | -138.9M | ↓ 36.07% |
Financing Cash Flow | -388.0M | ↑ 21.44% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 603.5M | ↑ 6.8% |
Investing Cash Flow | -99.1M | ↓ 28.69% |
Financing Cash Flow | -477.4M | ↑ 23.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 724.7M | ↑ 20.09% |
Investing Cash Flow | -100.4M | ↑ 1.29% |
Financing Cash Flow | -743.9M | ↑ 55.84% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 908.8M | ↑ 25.41% |
Investing Cash Flow | -314.1M | ↑ 212.98% |
Financing Cash Flow | -590.5M | ↓ 20.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 859.1M | ↓ 5.47% |
Investing Cash Flow | -139.4M | ↓ 55.62% |
Financing Cash Flow | -716.0M | ↑ 21.25% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 90.8M | ↓ 62.32% |
Investing Cash Flow | -7.1M | ↓ 88.69% |
Financing Cash Flow | -64.5M | ↓ 75.6% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 219.2M | ↑ 141.26% |
Investing Cash Flow | -33.5M | ↑ 371.61% |
Financing Cash Flow | -188.8M | ↑ 192.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 245.4M | ↑ 11.99% |
Investing Cash Flow | -48.7M | ↑ 45.21% |
Financing Cash Flow | -177.3M | ↓ 6.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 303.6M | ↑ 23.72% |
Investing Cash Flow | -50.0M | ↑ 2.73% |
Financing Cash Flow | -285.4M | ↑ 61.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 153.3M | ↓ 49.53% |
Investing Cash Flow | -22.4M | ↓ 55.26% |
Financing Cash Flow | -137.6M | ↓ 51.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 266.8M | ↑ 74.09% |
Investing Cash Flow | -42.9M | ↑ 91.69% |
Financing Cash Flow | -227.4M | ↑ 65.24% |
Sell
Neutral
Buy
Mettler-toledo International Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Mettler-toledo International Inc. | -8.99% | -26.12% | 2.21% | 14.74% | 79.88% |
![]() Idexx Laboratories, Inc. | -14.4% | -11.4% | 34.21% | 11.23% | 75.67% |
![]() Agilent Technologies Inc. | -8.85% | -16.86% | -8.0% | 10.78% | 56.92% |
![]() Thermo Fisher Scientific, Inc. | -9.45% | -10.09% | -0.2% | 14.64% | 103.68% |
![]() Danaher Corp. | -6.08% | -0.68% | -3.95% | 15.22% | 127.01% |
![]() Iqvia Holdings Inc. | -12.38% | 0.92% | 8.62% | 24.82% | 51.26% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Mettler-toledo International Inc. | 28.3 | 28.3 | 2.81 | 40.69 | 0.3 | 0.22 | 0.0 | -4.1 |
![]() Idexx Laboratories, Inc. | 45.9 | 45.9 | 7.21 | 9.84 | 1.02 | 0.24 | 0.0 | 13.17 |
![]() Agilent Technologies Inc. | 28.93 | 28.93 | 2.36 | 5.42 | 0.21 | 0.09 | 0.01 | 18.99 |
![]() Thermo Fisher Scientific, Inc. | 34.57 | 34.57 | 4.28 | 22.38 | 0.13 | 0.05 | 0.0 | 113.36 |
![]() Danaher Corp. | 29.09 | 29.09 | 3.24 | 8.83 | 0.13 | 0.06 | 0.0 | 70.06 |
![]() Iqvia Holdings Inc. | 34.75 | 34.75 | 1.48 | 10.31 | 0.2 | 0.05 | 0.0 | 31.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Mettler-toledo International Inc. | Hold | $24.5B | 79.88% | 28.3 | 22.48% |
![]() Idexx Laboratories, Inc. | Buy | $36.3B | 75.67% | 45.9 | 22.52% |
![]() Agilent Technologies Inc. | Buy | $32.3B | 56.92% | 28.93 | 16.2% |
![]() Thermo Fisher Scientific, Inc. | Buy | $195.4B | 103.68% | 34.57 | 13.14% |
![]() Danaher Corp. | Buy | $183.2B | 127.01% | 29.09 | 20.95% |
![]() Iqvia Holdings Inc. | Buy | $37.0B | 51.26% | 34.75 | 7.47% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
WCM Investment Management
FMR Inc
Capital Research & Mgmt Co - Division 3
mettler toledo is a global manufacturer and marketer of precision instruments for use in laboratory, industrial and food retailing applications. the company has strong worldwide leadership positions. a significant majority of our instrument sales are in segments in which we are the global leader. in addition to a broad product offering, we have one of the largest global sales and service organizations among precision instrument companies. we focus on the high value-added segments of our markets by providing innovative instruments that often integrate various technologies including application-specific solutions for customers. we design our instruments not only to gather valuable data but also to facilitate the processing and transfer of this data into customers' management information systems.
Organization | Mettler-toledo International Inc. |
Employees | 16400 |
CEO | Mr. Patrick K. Kaltenbach |
Industry | Health Technology |
Lockheed Martin Corporation
$1,108.07
-0.91%
Avantor Inc
$1,108.07
-0.91%
Nio Inc.
$1,108.07
-0.91%
The Walt Disney Company
$1,108.07
-0.91%
Celanese Corporation
$1,108.07
-0.91%
Edwards Lifesciences Corp.
$1,108.07
-0.91%
Core Msci Total Intl Stk Ishares Etf
$1,108.07
-0.91%
Celsius Holdings Inc
$1,108.07
-0.91%
Crowdstrike Holdings, Inc.
$1,108.07
-0.91%